Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

Background: There are no head-to-head studies comparing the efficacy of the Bruton tyrosine kinase inhibitors, zanubrutinib and acalabrutinib, in relapsed or refractory chronic lymphocytic leukemia (R/R CLL). Objective: To compare the relative efficacy of zanubrutinib and acalabrutinib in R/R CLL us...

Full description

Saved in:
Bibliographic Details
Main Authors: Mazyar Shadman, Jennifer R. Brown, Rhys Williams, Leyla Mohseninejad, Keri Yang, Pal Rakonczai, Nicole Lamanna, Sheng Xu, Aileen Cleary Cohen, Susan M. O’Brien, Alessandra Tedeschi, Constantine S. Tam
Format: Article
Language:English
Published: SAGE Publishing 2025-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251340554
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1177/17588359251340554

Similar Items